Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Active as of 2024-11-01 |
<Citation xmlns="http://hl7.org/fhir">
<id value="267247"/>
<meta>
<versionId value="1"/>
<lastUpdated value="2024-08-01T12:37:46.381Z"/>
<profile
value="http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: Citation 267247</b></p><a name="267247"> </a><a name="hc267247"> </a><a name="267247-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 1; Last updated: 2024-08-01 12:37:46+0000</p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-journal-article-citation.html">JournalArticleCitation</a></p></div><p><b>url</b>: <a href="Citation-267247.html">Citation 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.</a></p><p><b>identifier</b>: FEvIR Object Identifier/267247, <code>https://pubmed.ncbi.nlm.nih.gov</code>/15832493, <a href="http://terminology.hl7.org/6.0.2/NamingSystem-uri.html" title="As defined by RFC 3986 (http://www.ietf.org/rfc/rfc3986.txt)(with many schemes defined in many RFCs). For OIDs and UUIDs, use the URN form (urn:oid:(note: lowercase) and urn:uuid:). See http://www.ietf.org/rfc/rfc3001.txt and http://www.ietf.org/rfc/rfc4122.txt
This oid is used as an identifier II.root to indicate the the extension is an absolute URI (technically, an IRI). Typically, this is used for OIDs and GUIDs. Note that when this OID is used with OIDs and GUIDs, the II.extension should start with urn:oid or urn:uuid:
Note that this OID is created to aid with interconversion between CDA and FHIR - FHIR uses urn:ietf:rfc:3986 as equivalent to this OID. URIs as identifiers appear more commonly in FHIR.
This OID may also be used in CD.codeSystem.">Uniform Resource Identifier (URI)</a>/urn:oid:2.16.840.1.113883.4.642.40.44.15.47</p><p><b>version</b>: 2.0.0-ballot</p><p><b>title</b>: 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.</p><p><b>status</b>: Active</p><p><b>date</b>: 2024-11-01 10:20:00+0000</p><p><b>publisher</b>: HL7 International / Clinical Decision Support</p><p><b>contact</b>: HL7 International / Clinical Decision Support: <a href="http://www.hl7.org/Special/committees/dss">http://www.hl7.org/Special/committees/dss</a></p><p><b>description</b>: </p><div><p>This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>
</div><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="http://hl7.org/fhir/R5/codesystem-citation-classification-type.html#citation-classification-type-fevir-platform-use">Citation Classification Type fevir-platform-use</a>: FEvIR Platform Use</td><td><span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier medline-base}">Medline Base</span></td></tr></table><p><b>jurisdiction</b>: <span title="Codes:{http://unstats.un.org/unsd/methods/m49/m49.htm 001}">World</span></p><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>
</div><p><b>approvalDate</b>: 2005-05-18</p><p><b>lastReviewDate</b>: 2019-11-09</p><p><b>author</b>: Computable Publishing®: MEDLINE-to-FEvIR Converter: </p><blockquote><p><b>classification</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/citation-classification-type citation-source}">Citation Source</span></p><p><b>classifier</b>: <span title="Codes:">MEDLINE</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/citation-classification-type medline-owner}">MEDLINE Citation Owner</span></p><p><b>classifier</b>: <span title="Codes:{https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value NLM}">National Library of Medicine, Index Section</span></p></blockquote><p><b>currentState</b>: <span title="Codes:{http://hl7.org/fhir/citation-status-type medline-medline}">Medline Citation Status of Medline</span>, <span title="Codes:{http://hl7.org/fhir/citation-status-type pubmed-publication-status-ppublish}">PubMed PublicationStatus of ppublish</span></p><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title="Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-pubmed}">PubMed Pubstatus of Pubmed</span></p><p><b>period</b>: ?? --> 2005-04-19 09:00:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title="Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-medline}">PubMed Pubstatus of Medline</span></p><p><b>period</b>: ?? --> 2005-05-19 09:00:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title="Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-entrez}">PubMed Pubstatus of Entrez</span></p><p><b>period</b>: ?? --> 2005-04-19 09:00:00+0000</p></blockquote><blockquote><p><b>citedArtifact</b></p><p><b>identifier</b>: <code>https://pubmed.ncbi.nlm.nih.gov</code>/15832493, <code>https://doi.org</code>/10.2165/00024677-200201060-00006</p><h3>Titles</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Language</b></td><td><b>Text</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/title-type primary}">Primary title</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">English</span></td><td><div><p>Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.</p>
</div></td></tr></table><h3>Abstracts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Text</b></td></tr><tr><td style="display: none">*</td><td><div><p><AbstractText Label="UNLABELLED">Rosiglitazone, a thiazolidinedione with a different side chain from those of troglitazone and pioglitazone, reduces plasma glucose levels and glucose production and increases glucose clearance in patients with type 2 diabetes mellitus. Insulin sensitivity, pancreatic beta-cell function and surrogate markers of cardiovascular risk factors are significantly improved by rosiglitazone. Double-blind trials of 8 to 26 weeks of rosiglitazone 4 or 8 mg/day monotherapy indicate significant decreases in fasting plasma glucose (-2 to -3 mmol/L with 8 mg/day) and glycosylated hemoglobin levels [HbA(1c); -0.6 to -0.7% (-0.8 to -1.1% in drug-naive patients) with 8 mg/day]. Significant decreases in hyperglycemic markers occurred when rosiglitazone was combined with metformin (HbA(1c) -0.8 to -1.0%), a sulfonylurea (-1.4%) or insulin (-1.2%) for 26 weeks versus little change with active comparator monotherapy. Efficacy was maintained in trials of < or =2 years, and was also apparent in various ethnic subgroups, elderly patients and both obese and nonobese patients. Rosiglitazone is currently not indicated in combination with injected insulin. It should be administered in conjunction with diet and exercise regimens. Rosiglitazone is generally well tolerated. Despite rare individual reports of liver function abnormalities in rosiglitazone recipients, the incidence of these in clinical trials (< or =2 years' duration) was similar to that in placebo and active comparator groups. Fluid retention associated with rosiglitazone may be the cause of the increased incidence of anemia in clinical trials, and also means that patients should be monitored for signs of heart failure during therapy. Although bodyweight is increased overall with rosiglitazone therapy, increases are in subcutaneous, not visceral, fat; hepatic fat is decreased. The pharmacokinetic profile of rosiglitazone is not substantially altered by age or renal impairment, nor are there important drug interactions. Rosiglitazone is not indicated in patients with active liver disease or increased liver enzymes.
<strong>CONCLUSIONS:</strong> Oral rosiglitazone 4 or 8 mg/day provides significant antihyperglycemic efficacy and is generally well tolerated, both as monotherapy and in combination with other antihyperglycemic agents, in patients with type 2 diabetes mellitus who do not have active liver disease. Long-term data are required before conclusions can be drawn about the clinical significance of positive changes to surrogate markers of cardiovascular disease risk and improvements to pancreatic beta-cell function. Rosiglitazone significantly improves insulin sensitivity and, as such, is a welcome addition to the treatment options for patients with type 2 diabetes mellitus.</p>
</div></td></tr></table><blockquote><p><b>publicationForm</b></p><blockquote><p><b>publishedIn</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/published-in-type D020492}">Periodical</span></p><p><b>identifier</b>: Print ISSN Type/1175-6349, ISOAbbreviation/Treat Endocrinol, ISSN Linking/1175-6349, Medline Title Abbreviation/Treat Endocrinol, NLM Unique ID/101132977</p><p><b>title</b>: Treatments in endocrinology</p><p><b>publisherLocation</b>: New Zealand</p></blockquote><p><b>citedMedium</b>: <span title="Codes:{http://hl7.org/fhir/cited-medium print}">Print</span></p><p><b>volume</b>: 1</p><p><b>issue</b>: 6</p><p><b>articleDate</b>: 2002</p><p><b>publicationDateText</b>: 2002</p><p><b>language</b>: <span title="Codes:{urn:ietf:bcp:47 en}">English</span></p><p><b>pageString</b>: 411-4</p></blockquote><h3>WebLocations</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Classifier</b></td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/artifact-url-classifier abstract}">Abstract</span></td><td><a href="https://pubmed.ncbi.nlm.nih.gov/15832493/">https://pubmed.ncbi.nlm.nih.gov/15832493/</a></td></tr></table><blockquote><p><b>classification</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type publishing-model}">Publishing Model</span></p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier Print}">Print</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type chemical}">Chemical</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D007004}">Hypoglycemic Agents</span>, <span title="Codes:{https://meshb.nlm.nih.gov/ D045162}">Thiazolidinediones</span>, <span title="Codes:{https://www.cas.org/support/documentation/chemical-substances 05V02F2KDG}, {https://meshb.nlm.nih.gov/ D000077154}">Rosiglitazone</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">MeSH heading</span></p><p><b>artifactAssessment</b>: <a href="#hc267247/meshHeading0">ArtifactAssessment: artifact[x] = this resource</a></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type publication-type}">Publication type</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D016428}">Journal Article</span>, <span title="Codes:{https://meshb.nlm.nih.gov/ D016454}">Review</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type knowledge-artifact-type}">Knowledge Artifact Type</span></p><p><b>classifier</b>: <span title="Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}">Journal Article</span></p><p><b>artifactAssessment</b>: Classifier added by Computable Publishing LLC</p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type citation-subset}">Citation subset</span></p><p><b>classifier</b>: <span title="Codes:{https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset IM}">IM</span></p></blockquote><blockquote><p><b>contributorship</b></p><p><b>complete</b>: true</p><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc267247/contributor0">Wagstaff AJ</a></p><p><b>forenameInitials</b>: AJ</p><p><b>affiliation</b>: Adis International Inc., Langhorne, Pennsylvania, USA. demail@adis.com</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href="#hc267247/contributor1">Goa KL</a></p><p><b>forenameInitials</b>: KL</p></blockquote></blockquote></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor0</b></p><a name="267247/contributor0"> </a><a name="hc267247/contributor0"> </a><a name="267247/contributor0-en-US"> </a><p><b>name</b>: Antona J Wagstaff </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Practitioner #contributor1</b></p><a name="267247/contributor1"> </a><a name="hc267247/contributor1"> </a><a name="267247/contributor1-en-US"> </a><p><b>name</b>: Karen L Goa </p></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: ArtifactAssessment #meshHeading0</b></p><a name="267247/meshHeading0"> </a><a name="hc267247/meshHeading0"> </a><a name="267247/meshHeading0-en-US"> </a><p><b>artifact</b>: <a href="#hc267247">Citation 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.</a></p><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D003924}">Diabetes Mellitus, Type 2</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ Q000188}">drug therapy</span></p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">is Major topic</span></td><td><span title="Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49488}">Yes</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D006801}">Humans</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">qualifier</span></td><td><span title="Codes:">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D007004}">Hypoglycemic Agents</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ Q000008}">administration & dosage</span></p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">is Major topic</span></td><td><span title="Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49488}">Yes</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D000077154}">Rosiglitazone</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">qualifier</span></td><td><span title="Codes:">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: Classifier</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/cited-artifact-classification-type mesh-heading}">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ D045162}">Thiazolidinediones</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title="Codes:">qualifier</span></p><p><b>classifier</b>: <span title="Codes:{https://meshb.nlm.nih.gov/ Q000008}">administration & dosage</span></p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">is Major topic</span></td><td><span title="Codes:{https://ncithesaurus.nci.nih.gov/ncitbrowser C49488}">Yes</span></td></tr></table></blockquote></blockquote></blockquote></div>
</text>
<contained>
<Practitioner>
<id value="contributor0"/>
<name>
<family value="Wagstaff"/>
<given value="Antona J"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="contributor1"/>
<name>
<family value="Goa"/>
<given value="Karen L"/>
</name>
</Practitioner>
</contained>
<contained>
<ArtifactAssessment>
<id value="meshHeading0"/>
<artifactReference>
<reference value="#"/>
<type value="Citation"/>
</artifactReference>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D003924"/>
<display value="Diabetes Mellitus, Type 2"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000188"/>
<display value="drug therapy"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49488"/>
<display value="Yes"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D006801"/>
<display value="Humans"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D007004"/>
<display value="Hypoglycemic Agents"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000008"/>
<display value="administration & dosage"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49488"/>
<display value="Yes"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000077154"/>
<display value="Rosiglitazone"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D045162"/>
<display value="Thiazolidinediones"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000008"/>
<display value="administration & dosage"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49488"/>
<display value="Yes"/>
</coding>
</classifier>
</component>
</component>
</content>
</ArtifactAssessment>
</contained>
<url value="https://fevir.net/resources/Citation/267247"/>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="FEvIR Object Identifier"/>
</type>
<system value="https://fevir.net"/>
<value value="267247"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="15832493"/>
</identifier>
<identifier>
<system value="urn:ietf:rfc:3986"/>
<value value="urn:oid:2.16.840.1.113883.4.642.40.44.15.47"/>
</identifier>
<version value="2.0.0-ballot"/>
<title
value="15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus."/>
<status value="active"/>
<date value="2024-11-01T10:20:00+00:00"/>
<publisher value="HL7 International / Clinical Decision Support"/>
<contact>
<name value="HL7 International / Clinical Decision Support"/>
<telecom>
<system value="url"/>
<value value="http://www.hl7.org/Special/committees/dss"/>
</telecom>
</contact>
<description
value="This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide."/>
<useContext>
<code>
<system value="http://hl7.org/fhir/citation-classification-type"/>
<code value="fevir-platform-use"/>
<display value="FEvIR Platform Use"/>
</code>
<valueCodeableConcept>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="medline-base"/>
<display value="Medline Base"/>
<userSelected value="false"/>
</coding>
</valueCodeableConcept>
</useContext>
<jurisdiction>
<coding>
<system value="http://unstats.un.org/unsd/methods/m49/m49.htm"/>
<code value="001"/>
<display value="World"/>
</coding>
</jurisdiction>
<copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
<approvalDate value="2005-05-18"/>
<lastReviewDate value="2019-11-09"/>
<author>
<name value="Computable Publishing®: MEDLINE-to-FEvIR Converter"/>
</author>
<classification>
<type>
<coding>
<system value="http://hl7.org/fhir/citation-classification-type"/>
<code value="citation-source"/>
<display value="Citation Source"/>
</coding>
</type>
<classifier>
<text value="MEDLINE"/>
</classifier>
</classification>
<classification>
<type>
<coding>
<system value="http://hl7.org/fhir/citation-classification-type"/>
<code value="medline-owner"/>
<display value="MEDLINE Citation Owner"/>
</coding>
</type>
<classifier>
<coding>
<system
value="https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value"/>
<code value="NLM"/>
<display value="National Library of Medicine, Index Section"/>
<userSelected value="false"/>
</coding>
</classifier>
</classification>
<currentState>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="medline-medline"/>
<display value="Medline Citation Status of Medline"/>
</coding>
</currentState>
<currentState>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="pubmed-publication-status-ppublish"/>
<display value="PubMed PublicationStatus of ppublish"/>
</coding>
</currentState>
<statusDate>
<activity>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="pubmed-pubstatus-pubmed"/>
<display value="PubMed Pubstatus of Pubmed"/>
</coding>
</activity>
<period>
<end value="2005-04-19T09:00:00.000Z"/>
</period>
</statusDate>
<statusDate>
<activity>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="pubmed-pubstatus-medline"/>
<display value="PubMed Pubstatus of Medline"/>
</coding>
</activity>
<period>
<end value="2005-05-19T09:00:00.000Z"/>
</period>
</statusDate>
<statusDate>
<activity>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="pubmed-pubstatus-entrez"/>
<display value="PubMed Pubstatus of Entrez"/>
</coding>
</activity>
<period>
<end value="2005-04-19T09:00:00.000Z"/>
</period>
</statusDate>
<citedArtifact>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="15832493"/>
</identifier>
<identifier>
<system value="https://doi.org"/>
<value value="10.2165/00024677-200201060-00006"/>
</identifier>
<title>
<type>
<coding>
<system value="http://hl7.org/fhir/title-type"/>
<code value="primary"/>
<display value="Primary title"/>
</coding>
</type>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="English"/>
</coding>
</language>
<text
value="Spotlight on rosiglitazone in the management of type 2 diabetes mellitus."/>
</title>
<abstract>
<text
value="<AbstractText Label="UNLABELLED">Rosiglitazone, a thiazolidinedione with a different side chain from those of troglitazone and pioglitazone, reduces plasma glucose levels and glucose production and increases glucose clearance in patients with type 2 diabetes mellitus. Insulin sensitivity, pancreatic beta-cell function and surrogate markers of cardiovascular risk factors are significantly improved by rosiglitazone. Double-blind trials of 8 to 26 weeks of rosiglitazone 4 or 8 mg/day monotherapy indicate significant decreases in fasting plasma glucose (-2 to -3 mmol/L with 8 mg/day) and glycosylated hemoglobin levels [HbA(1c); -0.6 to -0.7% (-0.8 to -1.1% in drug-naive patients) with 8 mg/day]. Significant decreases in hyperglycemic markers occurred when rosiglitazone was combined with metformin (HbA(1c) -0.8 to -1.0%), a sulfonylurea (-1.4%) or insulin (-1.2%) for 26 weeks versus little change with active comparator monotherapy. Efficacy was maintained in trials of &lt; or =2 years, and was also apparent in various ethnic subgroups, elderly patients and both obese and nonobese patients. Rosiglitazone is currently not indicated in combination with injected insulin. It should be administered in conjunction with diet and exercise regimens. Rosiglitazone is generally well tolerated. Despite rare individual reports of liver function abnormalities in rosiglitazone recipients, the incidence of these in clinical trials (&lt; or =2 years' duration) was similar to that in placebo and active comparator groups. Fluid retention associated with rosiglitazone may be the cause of the increased incidence of anemia in clinical trials, and also means that patients should be monitored for signs of heart failure during therapy. Although bodyweight is increased overall with rosiglitazone therapy, increases are in subcutaneous, not visceral, fat; hepatic fat is decreased. The pharmacokinetic profile of rosiglitazone is not substantially altered by age or renal impairment, nor are there important drug interactions. Rosiglitazone is not indicated in patients with active liver disease or increased liver enzymes.
**CONCLUSIONS:** Oral rosiglitazone 4 or 8 mg/day provides significant antihyperglycemic efficacy and is generally well tolerated, both as monotherapy and in combination with other antihyperglycemic agents, in patients with type 2 diabetes mellitus who do not have active liver disease. Long-term data are required before conclusions can be drawn about the clinical significance of positive changes to surrogate markers of cardiovascular disease risk and improvements to pancreatic beta-cell function. Rosiglitazone significantly improves insulin sensitivity and, as such, is a welcome addition to the treatment options for patients with type 2 diabetes mellitus."/>
</abstract>
<publicationForm>
<publishedIn>
<type>
<coding>
<system value="http://hl7.org/fhir/published-in-type"/>
<code value="D020492"/>
<display value="Periodical"/>
</coding>
</type>
<identifier>
<type>
<coding>
<system
value="https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#issn"/>
<code value="Print"/>
<display value="Print"/>
</coding>
<text value="Print ISSN Type"/>
</type>
<system value="https://portal.issn.org"/>
<value value="1175-6349"/>
</identifier>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="XX"/>
<display value="Organization identifier"/>
</coding>
<text value="ISOAbbreviation"/>
</type>
<system
value="https://www.issn.org/services/online-services/access-to-the-ltwa/"/>
<value value="Treat Endocrinol"/>
</identifier>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="XX"/>
<display value="Organization identifier"/>
</coding>
<text value="ISSN Linking"/>
</type>
<system
value="https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/"/>
<value value="1175-6349"/>
</identifier>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="XX"/>
<display value="Organization identifier"/>
</coding>
<text value="Medline Title Abbreviation"/>
</type>
<system
value="https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html"/>
<value value="Treat Endocrinol"/>
</identifier>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="XX"/>
<display value="Organization identifier"/>
</coding>
<text value="NLM Unique ID"/>
</type>
<system
value="https://locatorplus.gov/cgi-bin/Pwebrecon.cgi?DB=local"/>
<value value="101132977"/>
</identifier>
<title value="Treatments in endocrinology"/>
<publisherLocation value="New Zealand"/>
</publishedIn>
<citedMedium>
<coding>
<system value="http://hl7.org/fhir/cited-medium"/>
<code value="print"/>
<display value="Print"/>
</coding>
</citedMedium>
<volume value="1"/>
<issue value="6"/>
<articleDate value="2002"/>
<publicationDateText value="2002"/>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="English"/>
</coding>
</language>
<pageString value="411-4"/>
</publicationForm>
<webLocation>
<classifier>
<coding>
<system value="http://hl7.org/fhir/artifact-url-classifier"/>
<code value="abstract"/>
<display value="Abstract"/>
</coding>
</classifier>
<url value="https://pubmed.ncbi.nlm.nih.gov/15832493/"/>
</webLocation>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="publishing-model"/>
<display value="Publishing Model"/>
<userSelected value="false"/>
</coding>
</type>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="Print"/>
<display value="Print"/>
<userSelected value="false"/>
</coding>
</classifier>
</classification>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="chemical"/>
<display value="Chemical"/>
<userSelected value="false"/>
</coding>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D007004"/>
<display value="Hypoglycemic Agents"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D045162"/>
<display value="Thiazolidinediones"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system
value="https://www.cas.org/support/documentation/chemical-substances"/>
<code value="05V02F2KDG"/>
<userSelected value="false"/>
</coding>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000077154"/>
<display value="Rosiglitazone"/>
<userSelected value="false"/>
</coding>
</classifier>
</classification>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
</type>
<artifactAssessment>
<reference value="#meshHeading0"/>
<type value="ArtifactAssessment"/>
</artifactAssessment>
</classification>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="publication-type"/>
<display value="Publication type"/>
</coding>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D016428"/>
<display value="Journal Article"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D016454"/>
<display value="Review"/>
<userSelected value="false"/>
</coding>
</classifier>
</classification>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="knowledge-artifact-type"/>
<display value="Knowledge Artifact Type"/>
<userSelected value="false"/>
</coding>
</type>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
<userSelected value="false"/>
</coding>
</classifier>
<artifactAssessment>
<display value="Classifier added by Computable Publishing LLC"/>
</artifactAssessment>
</classification>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="citation-subset"/>
<display value="Citation subset"/>
<userSelected value="false"/>
</coding>
</type>
<classifier>
<coding>
<system
value="https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset"/>
<code value="IM"/>
<display value="IM"/>
<userSelected value="false"/>
</coding>
</classifier>
</classification>
<contributorship>
<complete value="true"/>
<entry>
<contributor>
<reference value="#contributor0"/>
<type value="Practitioner"/>
<display value="Wagstaff AJ"/>
</contributor>
<forenameInitials value="AJ"/>
<affiliation>
<display
value="Adis International Inc., Langhorne, Pennsylvania, USA. demail@adis.com"/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#contributor1"/>
<type value="Practitioner"/>
<display value="Goa KL"/>
</contributor>
<forenameInitials value="KL"/>
</entry>
</contributorship>
</citedArtifact>
</Citation>
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#2.0.0-ballot based on FHIR 6.0.0-ballot2. Generated 2024-11-01
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change